BioVie

BioVie is a clinical-stage biopharmaceutical company developing innovative drug therapies for neurological disorders, neurodegenerative diseases, liver diseases, and certain cancers. In liver disease, the company’s orphan drug candidate BIV201 (continuous infusion of terlipressin) has FDA Fast Track designation and is currently being evaluated in a Phase 2 study in the U.S. for the treatment of refractory ascites, with topline results expected in early 2022. The company also plans to conduct a pivotal Phase 3 study of BIV201 for the treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) in 2022.